Tech Company Financing Transactions

F2G Funding Round

F2G secured a $60.8 million financing round on 8/13/2020. Backers included Cowen Capital Partners, Advent Life Sciences and Brace Pharma.

Transaction Overview

Company Name
Announced On
8/13/2020
Transaction Type
Venture Equity
Amount
$60,800,000
Round
Undisclosed
Proceeds Purpose
Proceeds from the financing will be used to fund F2G's late-stage clinical programs for their novel antifungal agent olorofim and organisational scale-up in preparation for commercialisation.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Lankro Way Eccles
Manchester, M30 0LX
UK
Email Address
Overview
F2G is a world leading UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections, with experienced management and board. F2G has discovered and developed a completely new class of antifungal agents called the orotomides.
Profile
F2G LinkedIn Company Profile
Social Media
F2G Company Twitter Account
Company News
F2G News
Facebook
F2G on Facebook
YouTube
F2G on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Ian Nicholson
  Ian Nicholson LinkedIn Profile  Ian Nicholson Twitter Account  Ian Nicholson News  Ian Nicholson on Facebook
Chief Financial Officer
Ralf Schmid
  Ralf Schmid LinkedIn Profile  Ralf Schmid Twitter Account  Ralf Schmid News  Ralf Schmid on Facebook
Chief Medical Officer
Emma Harvey
  Emma Harvey LinkedIn Profile  Emma Harvey Twitter Account  Emma Harvey News  Emma Harvey on Facebook
Chief Medical Officer
John Rex
  John Rex LinkedIn Profile  John Rex Twitter Account  John Rex News  John Rex on Facebook
Chief Operating Officer
Michael Birch
  Michael Birch LinkedIn Profile  Michael Birch Twitter Account  Michael Birch News  Michael Birch on Facebook
Chief Scientific Officer
Tony Kennedy
  Tony Kennedy LinkedIn Profile  Tony Kennedy Twitter Account  Tony Kennedy News  Tony Kennedy on Facebook


 

 

Browse more venture capital transactions:

Prev: 8/13/2020: Allergy Amulet venture capital transaction
Next: 8/13/2020: TearClear venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary